Advertisement

Comparative Study of the Effect of Ace-Inhibitors and Other Antihypertensive Agents on Proteinuria in Diabetic Patients

  • M. De Courten
  • L. Böhlen
  • P. Weidmann

Abstract

The incidence and prevalence of renal failure secondary to diabetes mellitus has steadily increased over the past decade in the United States [1], so that diabetes is now the leading cause of end-stage renal failure [2]. Microalbuminuria (30–300 mg/24 h) predicts overt nephropathy (proteinuria > 300 mg/24 h) and chronic renal failure in diabetic subjects [3] and has a powerful association with macro vascular disease unexplained by simultaneous existing cardiovascular risk factors [4].

Keywords

Glomerular Filtration Rate Diabetic Nephropathy Angiotensin Converting Enzyme Inhibitor Systemic Blood Pressure Overt Nephropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    United States Renal Data System. USRDS 1990 Annual Data Report. Bethesda, Maryland: The National Institutes of Health, National Institutes of Diabetes and Digestive Diseases; 1990.Google Scholar
  2. 2.
    Centers for Disease Control. End-stage renal disease associated with diabetes. United States 1988. Morb Mortal Wkly Rep 1989; 38: 546–548.Google Scholar
  3. 3.
    Viberti GC, Hill RD, Jarrett RJ, Agryopoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet 1982; i: 1430–1432.CrossRefGoogle Scholar
  4. 4.
    Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736–741.PubMedCrossRefGoogle Scholar
  5. 5.
    Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 299: 230–233.PubMedCrossRefGoogle Scholar
  6. 6.
    Mogensen CE, Hansen KW. Preventing and postponing renal disease in insulin-dependent diabetes by glycémie and nonglycemic intervention. Contr Nephrol 1990; 78: 73–100.Google Scholar
  7. 7.
    Viberti GC, Yip-Messent J, Morocutti A. Diabetic Nephropathy. Diabetes Care 1992; 15: 1216–1225.PubMedCrossRefGoogle Scholar
  8. 8.
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A, Mathiesen ER. Natural history of diabetic complications: early detection and progression (Symposium). Diabetic Med 1991; 8: S33–S37.CrossRefGoogle Scholar
  9. 9.
    Hasslacher Ch, Wolfrum M, Stech G, Wahl P, Ritz E. Diabetische Nephropathie bei Typ-II-Diabetes. Dtsch Med Wochenschr 1987; 112: 1445–1449.PubMedCrossRefGoogle Scholar
  10. 10.
    Nelson RG, Pettitt DJ, Baird HR, Charles MA, Liu QZ, Bennett PH, Knowler WC. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of Type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993; 36: 998–1001.PubMedCrossRefGoogle Scholar
  11. 11.
    Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study on mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics). II: associated risk factors. Diabetologia 1990; 33: 542–548.PubMedCrossRefGoogle Scholar
  12. 12.
    Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991; 121: 2 Pt 1: 586–590.PubMedCrossRefGoogle Scholar
  13. 13.
    Borch-Johnsen K, Kreiner S. Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651–1654.PubMedCrossRefGoogle Scholar
  14. 14.
    Christiansen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7: suppl. 2: 109–113.Google Scholar
  15. 15.
    Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen E, Svendsen PA. Effects of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443–1447.PubMedCrossRefGoogle Scholar
  16. 16.
    Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086–1091.PubMedCrossRefGoogle Scholar
  17. 17.
    Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 1992; 41: 912–919.PubMedCrossRefGoogle Scholar
  18. 18.
    Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.PubMedCrossRefGoogle Scholar
  19. 19.
    Walker WG, Hermann J, Yin D, Murphy RP, Patz A. Diuretics accelerate diabetic nephropathy in hypertensive insulin-dependent and non-insulin-dependent subjects. Trans Assoc Phys 1987; C305–C315.Google Scholar
  20. 20.
    Anderson S. Renal hemodynamics of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288–295.PubMedCrossRefGoogle Scholar
  21. 21.
    Epstein M. Calcium antagonists and the kidney: Implications for renal protection. Kidney Int 1992; 41: suppl. 36: S66–S72.Google Scholar
  22. 22.
    Johnston CI, Clappison BH, Anderson WP, Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol 1982; 49: 1401–1404.PubMedCrossRefGoogle Scholar
  23. 23.
    Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541–549.PubMedCrossRefGoogle Scholar
  24. 24.
    Björck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990; 300: 904–907.PubMedCrossRefGoogle Scholar
  25. 25.
    Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J Human Hypertens 1992; 6: suppl. 2: S23–S36.Google Scholar
  26. 26.
    Weidmann P, Bohlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582–584.PubMedGoogle Scholar
  27. 27.
    Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 471–474.PubMedCrossRefGoogle Scholar
  28. 28.
    D’Angelo A, Sartori L, Gambaro G, Giannini S, Malvasi L, Benetello P, Lavagnini T, Crepaldi G. Captopril in the treatment of hypertension in type I and type II diabetic patients. Postgrad Med J 1986; 62: suppl. 1: 69–72.PubMedGoogle Scholar
  29. 29.
    Zanella MT, Salgado BJL, Kohlmann O, Ribeiro AB. Converting enzyme inhibition: a therapeutical option for diabetic patients. Hypertension 1987; 9: 543.Google Scholar
  30. 30.
    Casado S, Carrasco MA, Arrieta FJ, Herrera JL. Effects of Captopril in diabetic patients with different degrees of blood pressure and proteinuria. Postgrad Med J 1988; 64: suppl. 3: 85.Google Scholar
  31. 31.
    Romero R, Sanmartí A, Salinas I, Teixidó J, Foz M, Caralps A. Utilidad de los inhibidores de la enzima conversiva de la angiotensina an el tratamiento de la nefropatia diabetica. Med Clin (Bare) 1988; 90: 494–496.Google Scholar
  32. 32.
    Valvo E, Bedogna P, Casagrande P, Panebianco R, Bommartini F, Olderizzi L, Rugiu C, Maschio G. Effects of Captopril on systemic and renal haemodynamics in patients with diabetic nephropathy and renal insufficiency. Postgrad Med J 1988; 64: suppl. 3: 89.Google Scholar
  33. 33.
    Doyle AE, Alford ME, Cooper M, De Luise M, Hammond G, Jerums G, Mashford M. A comparison of the effects of blood pressure reduction with Perindopril and nifedipine on micro-albuminuria in hypertensive and normotensive diabetics. J Hypertens 1989; 7: suppl. 6: S361.Google Scholar
  34. 34.
    Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor Captopril in hypertensive type II diabetic patients with nephropathy. J Cardio vase Pharmacol 1989; 14: 851–855.CrossRefGoogle Scholar
  35. 35.
    Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Nieto J, Sanchez M, Lozano L, Ortiz S, Lopez A, Jarillo MD. Hypertension and proteinuria in diabetic patients. Long-term effect of Captopril. Kidney Int 1990; 37: 1609–1610.Google Scholar
  37. 37.
    Slomowitz LA, Bergamo R, Grosvenor M, Kopple JD. Enalapril reduces albumin excretion in diabetic patients with low levels of microalbuminuria. Am J Nephrol 1990; 10: 457–462.PubMedCrossRefGoogle Scholar
  38. 38.
    Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ 1991; 303: 821–824.PubMedCrossRefGoogle Scholar
  39. 39.
    Bochicchio T, Ron O, Sandoval G, Bobadilla N, Ruiz A, Herrera-Acosta J. Effect of Captopril on proteinuria and renal hemodynamics in hypertensive type-II diabetic patients with nephropathy. Hypertension 1991; 17: 422.Google Scholar
  40. 40.
    Brusztyn M, Kobrin I, Fidel J, Ben-Ishay D. Improved kidney function with Cilazapril in hypertensive type II diabetics with chronic renal failure. J Cardiovasc Pharmacol 1991; 18: 337–341.CrossRefGoogle Scholar
  41. 41.
    Haisa S, Norii T, Takatori E, Got A, Morioka S, Uchida K, Himei H. Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria. J Diabetic Complications 1991; 5: 162–164.CrossRefGoogle Scholar
  42. 42.
    Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fauchald P, Endresen L, Djoseland O, Berg KJ. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetes with nephropathy. J Intern Med 1991; 229: 163–170.PubMedCrossRefGoogle Scholar
  43. 43.
    Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud P. Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 1991; 18: suppl. 2P: S165–S168.Google Scholar
  44. 44.
    Martello MA, Daccordi HA, Ferder LF, Inserra F, Panzalis MMC. Enalapril versus nifedipine in diabetic patients with hypertension and proteinuria. Diabetes 1991; 40: 506A.Google Scholar
  45. 45.
    Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of Captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81–87.PubMedCrossRefGoogle Scholar
  46. 46.
    Silvani G, Bondi A, Nizzoli M, Ruggiero F, Vallicelli A, Miglio F. Enalapril versus low protein diet: effects on microalbuminuria and kidney function in normotensive type I (insulin-dependent) diabetic patients with incipient nephropathy. Diabetes 1991; 40: suppl. 1: 441 A.Google Scholar
  47. 47.
    Bochicchio T, Ron O, Sandoval G, Rodriguez F, Ruiz A, Herrera-Acosta J. An-tiproteinuric effect of Captopril is associated with restoration of renal functional reserve (RFR) in NIDDM Patients with nephropathy. J Hypertens 1992; 10: suppl. 4: S134.Google Scholar
  48. 48.
    Fioretto P, Frigato F, Velussi M, Riva F, MuoUo B, Carraro A, Brocco E, Cipollina MR, Abaterusso C, Trevisan M, Crepaldi G, Nosadini R. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992; 5: 837–884.PubMedGoogle Scholar
  49. 49.
    Jungmann E, Haak T, Malanyn M, Mortasawi N, Scherberich J, Usadel KH. Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. J Hypertens 1992; 10: suppl. 4: S242.Google Scholar
  50. 50.
    Milagres R, Kohlmann O, Zanella MT, Ribeiro AB. Cilazapril reduces proteinuria in insulin dependent diabetes mellitus (IDDM) without change in renal hemodynamics. J Hypertens 1992; 10: suppl. 4: 276.Google Scholar
  51. 51.
    Romero R, Salinas I, Lucas A, Teixido J, Audi L, Sanmarti A. Comparative effects of Captopril versus nifedipine on proteinuria and renal function. Diabetes Res Clin Pract 1992; 17: 191–198.PubMedCrossRefGoogle Scholar
  52. 52.
    Romero R, Salinas I, Borräs M, Lucas A, Teixido J, Reverter JL, Abat E, Sanmarti A. Effects of angiotensin converting enzyme inhibitors in normotensive type 2 diabetic patients with microalbuminuria: a randomised study with control group. J Hypertens 1992; 10: suppl. 4: S102.Google Scholar
  53. 53.
    Tettamanti F, Zoppi A, Malmani GD, Lazzari P, Pasotti C, Corradi L, Fogari R. Effects of ramipril and nitrendipine on proteinuria in hypertensive patients with albuminuric NIDDM. J Hypertens 1992; 10: suppl. 4: S102.Google Scholar
  54. 54.
    Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud Ph, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993; 306: 175–192.PubMedCrossRefGoogle Scholar
  55. 55.
    Lacourciere Y, Nadeau A, Poirier L, Tancrède G. Captopril or conventional therapy in hypertensive type II diabetics. Hypertension 1993; 2: 786–794.CrossRefGoogle Scholar
  56. 56.
    O’Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Comparison of the effect of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens 1993; 7: 333–339.PubMedGoogle Scholar
  57. 57.
    O’Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993; 7: 327–332.PubMedGoogle Scholar
  58. 58.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.PubMedCrossRefGoogle Scholar
  59. 59.
    Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973–980.PubMedCrossRefGoogle Scholar
  60. 60.
    Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertension. Am J Hypertens 1991; 4: 291–296.PubMedGoogle Scholar
  61. 77.
    Schardijn GHC, van Eps LWS. Beta-2-microglobulin: its significance in the evaluation of renal function. Kidney Int 1987; 32: 635–641.PubMedCrossRefGoogle Scholar
  62. 78.
    Christensen CK, Lederballe Pedersen O, Mikkelsen E. Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta adrenergic blocking drugs. Clin Pharmacol Ther 1982; 32: 572–576.PubMedCrossRefGoogle Scholar
  63. 79.
    Böhlen LM, Weidmann P, de Courten M, Erne P, Shaw SG. Antihypertensive during effects on left ventricular hypertrophy: meta-analysis considering duration of treatment. Abstract of the 15th Scientific Meeting of the International Society of Hypertension, Melbourne, March 1994.Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • M. De Courten
  • L. Böhlen
  • P. Weidmann

There are no affiliations available

Personalised recommendations